Podcasts about ttr

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent weeks have been a whirlwind of activity in the pharmaceutical and biotech sectors, showcasing significant strides in scientific breakthroughs, regulatory advancements, and strategic industry maneuvers. Replimune's Vusolimogene Oderparepvec has emerged as a beacon of hope in the fight against advanced melanoma. This gene therapy, utilizing an oncolytic virus, has recently received a positive nod from an advisory committee for its Phase 1/2 trial. When combined with PD-1 checkpoint inhibitors, it holds promise for enhancing immune responses against tumors—a critical development in cancer treatment that may redefine therapeutic strategies. This advancement follows two prior FDA rejections, underscoring the multifaceted evaluation process drugs undergo before approval and demonstrating that perseverance can eventually lead to success. Meanwhile, AstraZeneca and Daiichi Sankyo have achieved a milestone with the European Union's approval of Datopotamab Deruxtecan for treating unresectable or metastatic triple-negative breast cancer (TNBC). As an antibody-drug conjugate targeting the Trop-2 protein, it offers new hope to TNBC patients who often have limited options. This approval underscores the potential of antibody-drug conjugates in oncology, supported by promising Phase 3 trial data. Regeneron Pharmaceuticals is enjoying notable revenue growth thanks to Dupixent, a monoclonal antibody addressing autoimmune and respiratory diseases. Such financial success underscores the expanding role of biologics in tackling chronic illnesses, reflecting a broader industry trend towards biologically-based treatments. In business news, Pharmanovia's licensing deal with Impact Therapeutics for Senaparib signifies strategic expansion in oncology therapeutics. Similarly, Kaigene's agreement with Taisho Pharmaceutical highlights ongoing interest in autoimmune therapies, illustrating how companies are leveraging partnerships to broaden their therapeutic horizons. Pfizer is on the brink of expanding its label for Ritlecitinib (Litfulo), a JAK3 inhibitor that showed positive results in Phase 3 trials for nonsegmental vitiligo. By targeting autoimmune pathways, this small molecule could offer new hope to vitiligo patients seeking effective treatments. Litfulo is advancing through regulatory stages following successful trials, poised to provide an oral alternative for non-segmental vitiligo—a potential game-changer that could improve patient compliance and expand treatment options beyond Incyte's Opzelura. However, not all news is positive. Novo Nordisk faced disappointment when its Ziltivekimab failed a Phase 3 trial for atherosclerotic cardiovascular disease with chronic kidney disease. Despite this setback, Novo Nordisk remains optimistic about ongoing trials Artemis and Hermes as potential lifelines for their CKD program. Success could diversify their portfolio and introduce novel therapeutic options for CKD patients. Additionally, financial hurdles surfaced as Daiichi Sankyo saw an 11% share drop due to an accounting error, and Alnylam Pharmaceuticals' market value took a hit following a lowered revenue forecast for its TTR drug. On a global scale, the Trump administration has allocated $600 million to GAVI for childhood immunizations worldwide. This funding reversal emphasizes ongoing efforts to ensure vaccine accessibility across the globe—an essential component of public health initiatives. The dynamic nature of these developments reflects both the potential and challenges within the pharmaceutical landscape. The promising avenues presented by gene therapy, antibody-drug conjugates, and JAK inhibitors are tempered by clinical setbacks and financial volatility, underscoring the rigorous demands faced by industry stakeholders. In other industry news, AbbVie's Skyrizi continues to thrive despite increasing competition in the psoriasis market. With sales reaching $5.55 billion in Q2 2026, Skyrizi demonstrates the sustained demand for innovative biologics that enhance treatment efficacy and safety profiles. Karyopharm Therapeutics remains committed to its XPO1 inhibitor Xpovio despite setbacks in other indications like endometrial cancer. Their focus on myelofibrosis illustrates a strategic pivot towards hematologic malignancies where unmet needs persist. Oral GLP-1 receptor agonists are gaining ground as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie for dominance in weight management solutions. These oral formulations promise increased accessibility over traditional injectables. Regulatory arenas continue to evolve with AbbVie's Rinvoq gaining European clearance for alopecia and vitiligo. Such approvals highlight regulatory bodies' critical role in expanding market access across diverse therapeutic areas. Strategic partnerships also abound as WellSpan Health collaborates with Hippocratic AI to integrate artificial intelligence into healthcare solutions—a growing trend aimed at enhancing clinical decision-making capabilities. Meanwhile, Apnimed's $192 million IPO success indicates strong investor confidence in novel therapeutics like its sleep apnea treatment—a reflection of biopharma's financing dynamics where targeted therapies draw significant interest. Overall, these updates paint a vivid picture of an industry characterized by relentless innovation through scientific research, strategic alliances, and regulatory progress—all aimed at improving patient outcomes amidst evolving market demands. The industry's focus on breakthrough technologies continues to shape global health initiatives by offering new opportunities for patient care across various conditions. As companies navigate this dynamic environment marked by both promise and challenge—their ability to innovate scientifically while engaging strategically with regulators will be crucial to bringing novel therapies effectively into clinical practice where they can make meaningful impacts on patients' lives worldwide.Support the show

VOV1 - Lần đầu tiên tại Việt Nam, Bệnh viện Hữu nghị Việt Đức đã thực hiện thành công ca ghép dương vật từ người cho chết não. Đây là ca ghép dương vật thứ 6 được ghi nhận trên thế giới, là thành tựu y học lớn khẳng định năng lực làm chủ kỹ thuật ghép mô phức hợp đỉnh cao của ngoại khoa Việt Nam.Sáng 29/07, Bệnh viện Hữu nghị Việt Đức thông tin tới báo chí về ca ghép này sau 1 tuần thực hiện. Bệnh nhân được ghép năm nay 43 tuổi, cao 1,7 mét, nặng 72kg, đã có vợ và 3 con. Theo Phó Giáo sư, Tiến sĩ Dương Đức Hùng, Giám đốc Bệnh viện Hữu nghị Việt Đức, bệnh nhân này từng bị bệnh, phải phẫu thuật cắt bỏ đoạn dương vật cách đây 4 năm tại Trung tâm Nam học, Bệnh viện Hữu nghị Việt Đức, sau đó thường xuyên đến khám định kỳ.“Dương vật của bệnh nhân từng bị cắt ngang gốc. Suốt 4 năm qua, điều này đã gây ra những bất tiện cho bệnh nhân khi đi tiểu, phải chuyển từ tư thế đứng sang tư thế ngồi. Thứ hai nữa là quan hệ tình dục hầu như không có. Thứ ba là bệnh nhân bị tâm lý nặng nề, tự ti. Bệnh nhân làm công việc kinh doanh, trước đây rất quảng giao, nhưng từ khi xảy ra bệnh tật, phải cắt dương vật, bệnh nhân phải trải qua khủng hoảng tâm lý rất kinh khủng”- PGS.TS Dương Đức Hùng cho biếtTrước khi quyết định ghép dương vật cho bệnh nhân này, các chuyên gia của Bệnh viện Hữu nghị Việt Đức đã hội chẩn đa chuyên khoa, tiến hành đánh giá toàn diện người bệnh, bao gồm các xét nghiệm huyết học, sinh hóa, chức năng tim, phổi và các thăm dò hình ảnh. Kết quả cho thấy người bệnh có tình trạng sức khỏe ổn định, không bị chống chỉ định về mặt chuyên môn và hệ thống mạch máu vùng ghép đáp ứng yêu cầu để được ghép dương vật. PGS.TS Dương Đức Hùng, Giám đốc Bệnh viện Hữu nghị Việt Đức thông tin về ca ghép

This podcast by Dr. Ron Witteles reviews new data on transthyretin amyloid cardiomyopathy (ATTR‑CM), highlighting differences in transthyretin stabilization between acoramidis and tafamidis across wild-type and variant disease. The discussion underscores the clinical importance of TTR stabilization, emerging biomarkers such as serum transthyretin, and the expanding therapeutic landscape in cardiac amyloidosis.

Drs. Dasgupta and Sarswat review how ATTR cardiomyopathy remains under-recognized despite its prevalence in older patients with heart failure, emphasizing clinical red flags across cardiac and systemic manifestations. They outline a practical diagnostic pathway that prioritizes early identification using light-chain evaluation, bone scintigraphy, and genetic testing to distinguish transthyretin subtypes and initiate timely, disease-modifying therapy.

Drs. Sarswat and Dasgupta discuss contemporary decision-making in treating transthyretin amyloidosis, comparing oral stabilizers with subcutaneous silencers and emphasizing earlier diagnosis, phenotype-driven therapy, and individual patient preferences. They highlight how neuropathy and autonomic dysfunction influence choice of mechanism, review practical considerations such as side-effect profiles, dosing logistics, and drug–drug interactions, and briefly touch on emerging approaches like amyloid-removing and gene-targeted therapies.

Offrir des jours de congés aux salariés quand ils et elles voyagent de façon plus éco-responsable. Une drôle d'idée pourtant déjà concrète. C'est l'entreprise Ubiq qui a ouvert la voie en France, la première à avoir mis en place un tel système. La société est spécialisée dans les solutions de bureaux en France.  Depuis janvier 2023, elle a mis en place le concept du TTR - le Temps de trajet responsable. Désormais, les salariés peuvent bénéficier de deux jours de congés supplémentaires par an, lorsqu'ils partent en voyage de façon plus respectueuse de l'écologie. Qu'est-ce que le temps de trajet responsable ? Comment ça marche ? Est-ce un geste principalement symbolique ? Écoutez la suite de cet épisode de "Maintenant vous savez". Un podcast Bababam Originals, écrit et réalisé par Johanna Cincinatis. Première diffusion : mai 2023 À écouter aussi : ⁠A quoi servent vraiment les moustiques ?⁠ ⁠Rachida Dati : comment reconnaître un conflit d'intérêt ?⁠ ⁠Qu'est-ce que l'autisme virtuel ?⁠ Retrouvez tous les épisodes de ⁠⁠"Maintenant vous savez".⁠⁠ Suivez Bababam sur ⁠⁠Instagram⁠⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Ayesha and Andrew discuss the April 15, 2026 issue of JBJS, along with an added dose of entertainment and pop culture. Listen at the gym, on your commute, or whenever your case is on hold! Link: JBJS website: https://jbjs.org/issue.php Sponsor: This episode is brought to you by JBJS Clinical Classroom. Subspecialties: Hip, Shoulder, Knee, Foot & Ankle, Orthpaedic Essentials, Trauma, Oncology, Hand & Wrist Chapters (00:00:02) - Case Is On Hold(00:01:32) - Top 10 in Biologics: Fractures and the Vancouver Classification(00:02:34) - A Giant in Orthopedics: Kenneth Krakow(00:03:24) - Osteochondral Grafting from the iliac crest(00:10:19) - iliac crest bone graft and harvesting(00:12:17) - Pyrocarbon Hemiarthroplasty (Stryker)(00:22:37) - Causal Inference from the Pyrocarbon Hemiarthro(00:24:35) - Preoperative cognitive and psychological factors associated with post-operative delir(00:34:29) - TTR amyloid and fibrosis in carpal tunnel syndrome

Teacher wellbeing has fallen to its lowest level since 2019, according to the 2025 Teacher Wellbeing Index from Education Support. The findings paint a stark picture across the profession: 76% of education staff report feeling stressed, while 36% are at risk of probable clinical depression. Almost half (49%) say their working environment negatively affects their mental health, and 40% feel they need more support from their school. So, what role do school leaders play in improving staff wellbeing and what practical changes could make the biggest difference? In this live Points of View discussion on TTR, we'll explore the latest data and debate what school leaders can realistically do to support their staff. On the panel: Rae Whitehouse, Gulcin Sesli, Rich Walkden, Tom Rogers and JP.

Michael Wright guides you through some of his highlights from Teachers Talk Connect 2026! He meets speakers, attendees and members of the TTR team to talk about their event takeaways and how they have found the day. Featuring TTR team including Rae Whitehouse, Louise Pickering and Amber Hardisty. Find out more about Connect and watch the mainstage talks in full here: https://www.ttradio.org/connect2026 2026 edition took place Saturday 14th March in Manchester. Come along in 2027? We would love to see you there! Register for our newsletter for all event updates or follow us on our various social channels.

VOV1 - Hôm nay, Bệnh viện Hữu nghị Việt Đức thông tin về việc thực hiện thành công ca ghép đa tạng Domino, trong đó bệnh nhân mắc bệnh lý di truyền amyloidosis được ghép đồng thời cả tim và gan. Cùng với đó, lá gan của bệnh nhân còn hoàn khoẻ mạnh đã được ghép cho một bệnh nhân ung thư gan khác.      Từ ca hiến tạng của gia đình nữ bệnh nhân bị tai nạn giao thông chết não, nam bệnh nhân 53 tuổi được chẩn đoán mắc bệnh lý hiếm gặp amyloidosis di truyền (thoái hóa bột) do đột biến gen. Căn bệnh này đã gây tổn thương đa cơ quan, đặc biệt là bệnh cơ tim thâm nhiễm tiến triển, bệnh nhân được chỉ định ghép tim - gan đồng thời nhằm vừa thay thế cơ tim bị thâm nhiễm amyloid vừa loại bỏ nguồn sản xuất protein TTR đột biến từ gan. Tuy nhiên gan của bệnh nhân hoàn toàn khoẻ mạnh, có thể sử dụng để ghép cho bệnh nhân khác.

Dr. Aaron Zelikovich discusses the utility of neurofilament light chain as a serum biomarker in peripheral neuropathy.  Show citation: Karam C. Clinical Utility of Serum Neurofilament Light Chain in Peripheral Neuropathy. Muscle Nerve. 2026;73(1):86-92. doi:10.1002/mus.70073 Show transcript: Dr. Aaron Zelikovich: Welcome to today's neurology minute. My name is Aaron Zelikovich, a neuromuscular specialist at Lenox Hill Hospital in New York City. Today, we will discuss a recent article on the utility of neurofilament light chain as a serum biomarker in peripheral neuropathy. It has been studied in other neurological diseases like ALS and multiple sclerosis, as in the 2024 study by Robert Fox et al, which highlighted the limitations of serum neurofilament light chain in patients with multiple sclerosis, since the elevation was inconsistent and tended to occur weeks after MRI changes, and was really only found to be helpful in certain clinical situations. The study we highlight today is a single-center retrospective study that highlights the opportunities and limitations of using serum neurofilament light chain as a biomarker to monitor treatment response and peripheral neuropathy. Serum neurofilament light chain has been shown as an indicator of neuronal injury in both central and peripheral nervous system disease that has been associated with axonal injury or degeneration. It is now commercially available. The authors in this study provide a real-world single-center retrospective study that looked at various forms of peripheral neuropathy over 12 months. Patients had to be evaluated and meet criteria for peripheral neuropathy with either genetic testing, nerve conduction studies, and/or clinical exams. Neuropathies included TTR amyloid, vasculitis, CMT, CIDP, GBS, and anti-MAG neuropathy. Patients with TTR amyloid who were treatment naive and had elevated serum neurofilament light chain showed a reduction in neurofilament light chain levels with treatment. Additionally, patients with CIDP who were treatment naive with elevated serum neurofilament light chain also showed a reduction in neurofilament light chain levels with treatment. All patients with idiopathic peripheral neuropathy had normal serum neurofilament light chain levels. However, serum neurofilament light chain can vary in patients based on age, if they have diabetes, renal dysfunction, and body weight. And this makes it really challenging to interpret it in an isolated setting. Serum neurofilament light chain is a new biomarker for peripheral neuropathies. It can be a supplemental tool in the appropriate clinical context. Future studies are needed to identify its potential to be used as a treatment response biomarker in neuropathies like CADP, GBS, and TTR amyloid. Thank you so much, and have a wonderful day. 

On this episodeAs we prepare to head into the new year, we revisit our favorites from last year. Have they held up? Have we even gotten to play them again?We talk about a couple of the games we've played in the last few weeks, and we wrap up with a sneak peak at our current adventure through the TTR series.MeepleSociety@mail.comSocial Media

Duncan, Eddie and Lee return with another episode of Shoot and Scoot, the Flames of War, Checkpoint Charlie and Team Yankee wargaming podcast. This episode we talk about how Eddie and Lee got on at the TTR flames of war tornie, answer some of our patron's many questions and have our Christmas pub quiz.

Doença genética rara, a amiloidose por transtirretina hereditária (ATTRv) é causada por alterações no gene TTR, responsável pela produção da proteína transtirretina.Por ser uma condição pouco conhecida, pode ser confundida com outras doenças, o que atrasa o diagnóstico e o início do tratamento adequado. Esse atraso, por sua vez, pode impactar diretamente a qualidade de vida dos pacientes.Neste episódio do DrauzioCast, o dr. Drauzio Varella conversa com o neurologista dr. Marcondes Cavalcante França Jr. e com o paciente Jorge Luiz Neves sobre como a ATTRv se manifesta e quais sinais precoces merecem atenção.Conteúdo produzido em parceria com a Astrazeneca.BR-45866. Material destinado a todos os públicos. Aprovado em Outubro/2025Veja também: SHUa: o que é ser diagnosticado com uma doença rara?

Offrir des jours de congés aux salariés quand ils et elles voyagent de façon plus éco-responsable. Une drôle d'idée pourtant déjà concrète. C'est l'entreprise Ubiq qui a ouvert la voie en France, la première à avoir mis en place un tel système. La société est spécialisée dans les solutions de bureaux en France.  Depuis janvier 2023, elle a mis en place le concept du TTR - le Temps de trajet responsable. Désormais, les salariés peuvent bénéficier de deux jours de congés supplémentaires par an, lorsqu'ils partent en voyage de façon plus respectueuse de l'écologie. Qu'est-ce que le temps de trajet responsable ? Comment ça marche ? Est-ce un geste principalement symbolique ? Écoutez la suite de cet épisode de "Maintenant vous savez". Un podcast Bababam Originals, écrit et réalisé par Johanna Cincinatis. Première diffusion : 3 mai 2023 À écouter aussi : A quoi servent vraiment les moustiques ? Rachida Dati : comment reconnaître un conflit d'intérêt ? Qu'est-ce que l'autisme virtuel ? Retrouvez tous les épisodes de ⁠"Maintenant vous savez".⁠ Suivez Bababam sur ⁠Instagram⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

Join Matt for his debut show on TTR! He is joined by David Curran, a teacher in a specialist dyslexia school, as they discuss how to best utilise AI with SEND learners. 

CME credits: 0.25 Valid until: 28-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-clinical-weight-of-ttr-what-the-latest-data-reveal/35934/ Learn about emerging data in transthyretin amyloid cardiomyopathy (ATTR-CM) from recent congresses, journal publications, and retrospective database analysis, with practical guidance on integrating these findings into clinical practice to inform treatment strategies and patient management. Findings include reduced atrial fibrillation events and lower rates of cardiovascular hospitalization and all-cause mortality from the Heart Failure Association of the ESC. In addition, a recent publication highlights early and sustained increases in serum transthyretin (TTR) levels that are independently associated with improved survival. Additional insights are drawn from the UK Biobank database, showing that lower TTR levels are linked with a higher burden of chronic comorbidities. =

Martin is joined by fellow TTR hosts Graham Stanley and Tom Rogers as they pay tribute to Phil Longwell, ELT teacher, who sadly passed away recently after a battle with cancer. 

CardioNerds (Drs. Rick Ferraro and Georgia Vasilakis Tsatiris) discuss ATTR cardiac amyloidosis with expert Dr. Justin Grodin. This episode is a must-listen for all who want to know how to diagnose and treat ATTR with current available therapies, as well as management of concomitant diseases through a multidisciplinary approach. We take a deep dive into the importance of genetic testing, not only for patients and families, but also for gene-specific therapies on the horizon. Dr. Grodin draws us a roadmap, guiding us through new experimental therapies that may reverse the amyloidosis disease process once and for all.  Audio editing by CardioNerds academy intern, Christiana Dangas. This episode was developed in collaboration with the American Society of Preventive Cardiology and supported by an educational grant from BridgeBio.  Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey.  US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here.  CardioNerds Cardiac Amyloid PageCardioNerds Episode Page Pearls: You must THINK about your patient having amyloid to recognize the pattern and make the diagnosis. Start with a routine ECG and TTE, and look for a disproportionately large heart muscle with relatively low voltages on the ECG.  Before you diagnose ATTR amyloidosis, AL amyloidosis must be ruled out (or ruled in) with serum light chains, serum/urine immunofixation, and/or tissue biopsy.  Genetic testing is standard of care for all patients and families with ATTR amyloidosis, and the future is promising for gene-specific treatments. Current FDA-approved treatments for TTR amyloidosis are TTR stabilizers and TTR silencers, but TTR fibril-depleting agents are on their way.  Early diagnosis of ATTR affords patients maximal benefit from current amyloidosis therapies.   TTR amyloidosis patients require a multidisciplinary approach for success, given the high number of concomitant diseases with cardiomyopathy.  Notes: Notes: Notes drafted by Dr. Georgia Vasilakis Tsatiris.  What makes you most suspicious of a diagnosis of cardiac amyloidosis from the typical heart failure patient?  You must have a strong index of suspicion, meaning you THINK that the patient could have cardiac amyloidosis, to consider it diagnostically. Some characteristics or “red flags” to not miss:   Disproportionately thick heart muscle with a relatively low voltages on EKG   Bilateral carpal tunnel syndrome – estimated that 1 in 10 people >65 years old will have amyloidosis   Previously tolerated antihypertensive medications  Atraumatic biceps tendon rupture   Bilateral carpal tunnel syndrome  Spinal stenosis   Concomitant with other diseases: HFpEF, low-flow low-gradient aortic stenosis  How would you work up a patient for cardiac amyloidosis?   Start with a routine ECG (looking for disproportionally low voltage) and routine TTE (looking for thick heart muscle)  CBC, serum chemistries, hepatic function panel, NT proBNP, and troponin levels  NOTE: It is critical to differentiate between amyloid light chain (AL amyloidosis) and transthyretin ATTR amyloidosis, as both make up 95-99% of amyloidosis cases.   Obtain serum free light chains, serum & urine electrophoresis, and serum & urine immunofixation to rule out AL amyloidosis. (See table below)  AL Amyloidosis ATTR Amyloidosis  → Positive serum free light chains and immunofixation (Abnormal M protein) → Tissue biopsy (endomyocardial, fat pad) to confirm diagnosis → Negative serum free light chains and immunofixation (ruled out AL amyloidosis) → Cardiac scintigraphy (Technetium pyrophosphate with SPECT imaging)  What treatment options do we have to offer now for ATTR CM, and how has this compared to prior years?   Before 2019, treatment options were limited outside of cardiac tr...

Show 316 Another Full Spectrum Cycling show! JK and Sven ramble through the past week and look at some upcoming bike events, chat craft beer and generally do what we've been doping since 2017! The Milwaukee Minute (or 5) The Slow Roll is Coming Soon! Sunday- September 21st! Bye, bye TTR - https://milwaukeerecord.com/food-drink/triple-taproom-kitchen-on-east-side-has-closed/  Talkin' Schmack  Full Moon Beach Ride this Saturday in Port Washington is looking good - https://www.facebook.com/events/1254108756203125 Videos from the Michigan Trip are up. Day 1 - https://youtu.be/Iqk2WP8rxY0  Day 2 - https://youtu.be/XB1cyybU9_Q  Day 3 - https://youtu.be/2yLTAU-06ds  Day 4 - https://youtu.be/uPlPzztJZek  Free-Fall Fest at Levis Mounds - September 19-20-21st 2025 Because JK Mentioned i show or 2 back and because I love Bristol 45 Diner. See all Full Spectrum Cycling Video Podcast Episodes here - https://www.youtube.com/playlist?list=PLblXPI1hYVGbwjJjdv_eJGMubhqRU4vwd  Show Beer - Dogfish Head - Grateful Dead Juicy Pale Ale GrAs beer geeks with a music problem, we couldn't resist teaming back up with this legendary band to continue our long, strange trip together with a brand-NEW beer, Grateful Dead Juicy Pale Ale!Clocking in at 5.3% ABV, this pale ale is brewed with Kernza® grains, granola and heaps of good karma for a refreshing, light-bodied beer that will leave you with nothin' left to do but smile, smile, smile. The addition of El Dorado and Azacca hops brings waves of tropical pineapple, mango, and passion fruit notes for a vibrant tapestry of alluring aromas and flavors that just keeps truckin' sip after refreshing sip. If you like this show PLEASE Subscribe in Apple Podcast - https://podcasts.apple.com/us/podcast/full-spectrum-cycling/id1569662493   Stuff for sale on Facebook Marketplace Call-in to 717-727-2453 and leave us a message about how cycling is making your life better! Shit Worth Doing August 9th - Port Washington, WI - Full Moon Beach Ride August 22nd, 23rd and 24th - MADE! - Portland, Oregon, Zidell Yards - https://made.bike   September 21st - Milwaukee, WI - The Slow Roll September 15th - Chequamegon MTB Festival - Cable, WI - https://www.cheqmtb.com/ September 19-20-21st 2025 - Free-Fall Fest - Levis Mounds, WI Bikes! Omnium Cargo Mini Max - Small - Copper - NEW! Omnium Cargo Electric Mini Max - Small - Galaxy Black Large Schlick Cycles 29+ Custom Build - Black Medium Schlick Cycles 29+ Custom Build - Orange Large Schlick Cycles Tatanka, Orange. 29+ Schlick Cycles frames for custom builds Contact info@everydaycycles.com Call-in to 717-727-2453 and leave us a message about how cycling is making your life better! =============================Equipment we use during the production of Full Spectrum Cycling:============================= Cameras Mevo Core - https://amzn.to/3VpGzmJ - (Amazon) Mevo Start - https://amzn.to/3ZG2B7y - (Amazon) Panasonic 25mm 1.7 lens - https://amzn.to/3OH8Ph0 - (Amazon) Olympus 12mm-42mm lens - https://amzn.to/4iiEyCO - (Amazon) Audio Rode Podcaster Pro II - https://amzn.to/3xKbRfI  (Amazon) Microphones Earthworks Ethos Microphone - https://amzn.to/4eR6kEC  (Amazon) MXL BCD-1 Dynamic Microphone - https://amzn.to/3Yigjx9  (Amazon) Rode Wireless Go II - https://amzn.to/3Su114D  (Amazon) Audio Technica BPHS1 Headset Mics - https://amzn.to/4cXebi2  (Amazon) Blue Compass Boom Arm - https://amzn.to/4cClJr1  (Amazon) Accessories Ulanzi Crab Tripod - https://amzn.to/3WIxWVk  (Amazon) Neewer Camera Desk Mount with Overhead Camera Mounting Arm and 1/4" Ball Head, 17" - 41" Adjustable Tabletop Light Stand with C Clamp - https://amzn.to/3Wuo5Bc  (Amazon) =============================Disclosure: Some of the links on this page may be affiliate links. Clicking these and making a purchase will directly support Fu...

Guest post by Christine Ramsey, Head of Client Operations Klearcom They say that "the worst type of problem is the one you can't see." This is especially true when it comes to empowering and enhancing Customer Experience (CX). For a business, there are very few challenges more costly than a poor customer journey or a negative review. In fact, one bad review can cause significant damage to a brand. As well as jeopardising customer retention, substandard CX can prevent referrals, undermine brand trust and hinder business growth. Given its impact on a company's long-term success, it is therefore imperative that CX is both tested and trusted. This means uncovering and understanding any blind spots (those problems that are hard or impossible to see) which could affect customer service and confidence levels. For multinational companies serving global customer bases, these undetected issues - such as poor call quality, communication errors and misrouted calls - across their Interactive Voice Response (IVR) systems could not only be disruptive but also brand damaging. IVR systems allow businesses to automate call interactions through the use of voice prompts and DTMF inputs. IVR systems are therefore intended to save businesses time and money, while seamlessly and successfully transferring the customer to the desired department or getting them to a resolution quickly through self-serve options. However, if unchecked and untested, blind spots in IVR systems can have the opposite effect - causing delays, customer frustration, and in more serious cases, even system outages. Because they tend to fly under the radar, they often affect customers long before anyone on the client side realizes there's a problem (which can be costly from a reputational and financial perspective.) For example, a customer trying to reach their network provider's service desk could be prompted by the IVR to state the desired department but then is misrouted to sales. Or there might be a customer service message during a holiday period which is incorrect, leading to confusion and dissatisfaction among large cohorts of customers. CX blind spots can have various knock-on effects on a business, from reputational damage and reduced revenues to customer churn and compliance failures. In sectors which are highly regulated or during peak periods when demand is high, blind spots can potentially be catastrophic. In addition, the aftermath of a blind spot or outage can negatively impact employee morale, with faults leading to more calls from frustrated customers, resulting in more pressure on staff. Testing IVR systems can ensure optimal performance and experience for all stakeholders. By identifying and rectifying blind spots, IVR testing drives success for both customers and businesses - upholding quality, empowering customer journeys, and reducing the risk of outages. Furthermore, Call Detail Records (CDRs) can assist organisations with technical information to get resolution on blind spots faster as it enables them to pinpoint exactly where the issues are and reduce time to resolution (TTR.) With tighter regulations and rising customer expectations, companies are feeling the pressure to deliver a standout customer experience. To keep up, they need to be proactively testing their systems to catch blind spots before they turn into outages or unhappy customers. At the end of the day, it's not just the customer journey on the line but the future of the business. See more stories here. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a...

Tom Rogers is joined live by Catherine McKinnell MP to discuss latest government policy on the apprenticeships for teachers policy. The programme will now run over 9 months instead of 12. The government hopes this will lead to more schools offering the programme as it can be run over one academic year. Will this reduce rigour? We ask the questions in this TTR special interview. 

Join Tony Harwood, Science teacher, for his debut show on TTR. He is joined by fellow teacher Yannick to discuss what it is like to teach in a challenging school and so much more! 

In her first ever TTR show, Huma talks about leadership across borders - in various international contexts. She is joined by guest Dr George Scorgie, the Dean of Student Activities at Robert College, Istanbul.

Michelle Hinds is joined by John Catt author and fellow TTR host Morgan Whitfield to discuss her new book 'Gifted? The shift to enrichment, challenge and equity'. Michelle and Morgan explore what giftedness truly means, looking at practical solutions to stretch and challenge students of all abilities and ways to overcome the barriers to equity. Circus themed chapters set the foundation for engaging, relevant and enlightening discussions framed by historical background information. You can get a copy of Morgan's book here. Use the code JCTTR2425 for 20% off at the checkout. 

Philip's journey with ATTR began with unexplained weight loss and gastrointestinal issues that puzzled doctors for years. Despite seeing multiple specialists, his condition remained undiagnosed until a physician at Johns Hopkins finally connected the dots, confirming ATTR. By then, Philip had lost 60 pounds and was on the brink of survival. In today's episode of On Rare, David Rintell, Head of Patient Advocacy at BridgeBio, and Mandy Rohrig, Senior Director of Patient Advocacy at BridgeBio Gene Therapy, speak with Philip and his wife, Sally, who has helped to navigate the frustrating medical system, advocate for answers, and ultimately helped Philip receive life-saving IV nutrition. After years of uncertainty, Philip finally found an expert team with the knowledge, treatment, and community they needed. Philip and Sally share their story of perseverance, partnership, and hope for a brighter future. Dr. Adam Castaño, head of the Amyloid Prevention Program at BridgeBio, provides a medical overview of TTR amyloidosis (ATTR), a rare, progressive disease caused by misfolded transthyretin (TTR) proteins that form amyloid deposits in different parts of the body such as the heart, the peripheral nervous system, and the gastrointestinal tract. These deposits lead to debilitating symptoms including heart failure, neuropathy, and digestive issues, often mimicking common age-related conditions and possibly contributing to underdiagnosis. ATTR can be hereditary, but it also develops in the general population (this is called wild type). Advancements in non-invasive imaging and specialized protein staining have improved early detection, offering hope for better disease management.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The CDC has rescheduled a vaccine meeting for April, while President Trump is considering Texas Republican Michael Burgess as the new director of the agency. J&J's Tremfya has won approval for expansion in treating Crohn's disease, while Adaptimmune is facing financial uncertainty despite sales of its T cell therapy. Alnylam's Amvuttra has been approved as the first RNAi silencer for a rare type of cardiomyopathy, setting up competition with Pfizer and BridgeBio. Sino Biological has developed reagents for the 2025-2026 influenza vaccine strains. In other news, J&J plans to boost US manufacturing following tariff threats, Novartis' Fabhata has been approved as the first therapy for a rare kidney disease, and Sanofi commits up to $1.9 billion for Dren Bio's bispecific antibody for autoimmune diseases. Paratek has acquired Optinose for up to $330 million, Purdue Pharma has filed for bankruptcy again to support an opioid settlement, and Novartis' Zolgensma has been found effective in older children.The FDA has approved Alnylam's Amvuttra as the first RNAi silencer for a rare type of cardiovascular disease called ATTR-CM, following the approval of BridgeBio's Attruzy for the same condition. This approval has sparked a three-way race in the rapidly expanding space, with Pfizer's Tafamidis also in the competition. Alnylam is optimistic about Amvuttra's unique mechanism of action, which targets the disease at its source by rapidly reducing the disease-causing TTR protein. This approval comes after Attruzy was also approved for polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in June 2022. This development has brought cardiovascular disease back into the spotlight, with other companies launching new drugs and treatments for various heart conditions.

CardioNerds Cardiac Amyloidosis Series Chair Dr. Rick Ferraro and Episode Lead Dr. Anna Radakrishnan discuss the biology of transthyretin amyloid cardiomyopathy (ATTR-CM ) with Dr. Daniel Judge.  Notes were drafted by Dr. Anna Radakrishnan. The audio was engineered by student Dr. Julia Marques.  This episode provides a comprehensive overview of transthyretin (ATTR) cardiac amyloidosis, a complex and rapidly evolving disease process. The discussion covers the key red flags for cardiac amyloidosis, the diagnostic pathway, and the implications of hereditary versus wild-type ATTR. Importantly, the episode delves into the current and emerging therapies for ATTR, including stabilizers, gene silencers, and promising treatments like CRISPR-Cas9 and antibody-based approaches. Dr. Judge shares his insights and excitement about the rapidly advancing field, highlighting the need for early diagnosis and the potential to improve long-term outcomes for patients with this condition.  Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey.  US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here.  CardioNerds Cardiac Amyloid PageCardioNerds Episode Page Pearls: - Biology of Transthyretin amyloid cardiomyopathy Maintain a high index of suspicion! Look for subtle (yet telling) signs like ventricular hypertrophy, discordant EKG findings, bilateral carpal tunnel syndrome, and spontaneous biceps tendon rupture.  Utilize the right diagnostic tests. Endomyocardial biopsy remains the gold standard, but non-invasive tools like PYP scan with SPECT imaging and genetic testing are essential for accurate diagnosis.  Differentiating hereditary from wild-type ATTR is critical, as genetic forms may have a more aggressive course and familial implications.  Early diagnosis and intervention significantly improve prognosis, making vigilance in screening and prompt treatment initiation essential.  The future is now! Cutting-edge therapies are transforming the treatment landscape, including TTR stabilizers, gene silencers, and emerging technologies like CRISPR-Cas9 and antibody-based treatments.  Notes - Biology of Transthyretin amyloid cardiomyopathy What is transthyretin amyloid (aTTR) and how is it derived?  Transthyretin (TTR) is a transport protein primarily synthesized by the liver, responsible for carrying thyroid hormones (thyroxine) and retinol (vitamin A) in the blood. It circulates as a tetramer, composed of four identical monomers, which is essential for its stability and function.  In transthyretin amyloid (ATTR) amyloidosis, the TTR protein becomes unstable, leading to its dissociation into monomers. These monomers misfold and aggregate into insoluble amyloid fibrils, which deposit extracellularly in tissues such as the heart, nerves, and gastrointestinal tract. This progressive amyloid deposition leads to organ dysfunction, including restrictive cardiomyopathy and neuropathy.  There are two main forms of ATTR amyloidosis: hereditary (variant) and wild-type (senile) ATTR.  Hereditary ATTR (ATTRv) is caused by mutations in the TTR gene. These mutations destabilize the TTR tetramer, making it more prone to dissociation. This increases misfolding and amyloid fibril formation, resulting in systemic amyloid deposition.   Wild-type ATTR (ATTRwt) occurs without genetic mutations and is primarily age-related. Over time, even normal TTR tetramers can become unstable, leading to gradual misfolding and amyloid deposition, particularly in the heart. ATTRwt is a common but often underdiagnosed cause of heart failure with preserved ejection fraction (HFpEF) in elderly individuals.  How does aTTR lead to deleterious effects in the heart and other organ systems?    Transthyretin amyloidosis leads to organ dysfunction through the deposition of misfolded TTR protein as amyloid fib...

On This Episode of the Defending The Edge Podcast with DefendEdge, the team talks about how AI could be used to predict earthquakes, ransomware groups decreasing their TTR, Black Basta's internal conflicts being shared with the threat intelligence community and more. 

In this episode Ben White, school leader, research enthusiast and education writer is joined by Dan Boorman in his TTR series ‘Classroom Chronicles' which explores this theme with teachers and school leaders from across our schools.

This week John Gibbs revisits his show over the past year and asks: what have I learned? With the help of guests Dennis Sherwood, Dr Edda Sant, Professor Ester Leslie, PhD researcher Hannah Robinson as well as fellow TTR hosts Brent Poland, Lucy Neuburger, and Paul Hazzard, John explores lessons including: The (un)reliability of exams The instrumentalism creeping into schools. Educating for democracy Loss of teacher autonomy How teachers use humour Embrassing mess    

Disciples!! Here it is – TTR 1982 Part 2 is here, and the final for 1982. 40 great tracks, hand-selected by yours truly, and of course a bonus ‘demo’ track from an important Thrash Metal band who’s NOT in the ‘Big 4’. Enjoy, and do so at a loud volume.m/ BLOCK ONE: 0:00:00 TTR Intro0:01:00 … … Continue reading →

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/management-of-amyloid-cardiomyopathy-and-polyneuropathy-9813SummaryIn this CME/CE podcast episode, Cardiologist Dr. Michelle Kittleson and Neurologist Dr. Chafic Karam discuss the multidisciplinary management of transthyretin amyloidosis (ATTR). They explore how ATTR affects both the heart and the nervous system, focusing on recognizing symptoms, diagnosing the disease, and managing treatment. Dr. Karam shares insights on peripheral neuropathy caused by amyloidosis, including clues that suggest amyloidosis over more common neuropathies. Dr. Kittleson highlights how cardiologists assess and manage TTR cardiomyopathy, emphasizing the importance of early diagnosis and the evolving therapeutic landscape. Together, they discuss the collaborative nature of care, the impact of new therapies on clinical outcomes, and the importance of raising awareness for ATTR.Learning ObjectivesDescribe the correct diagnostic algorithm for suspected ATTR, including interpretation of the monoclonal protein screen and indications for biopsy and genetic testingInitiate appropriate management, including disease-directed therapy and appropriate cardiac care, or referral when indicatedThis activity is accredited for CME/CE CreditAssociation of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Association of Black Cardiologists, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and ABC. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.25 contact hours (which does not include hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by an educational grant from Alnylam Pharmaceuticals Inc., and an educational grant from AstraZeneca Pharmaceuticals.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Disciples!! It feels like it’s been forever, even though it’s only been about a month and a half. It’s Time Travel Radio 1982!! For this series, there’ll be only two episodes for this year, but I did add a few more tracks to each episode. So, without further ado, TTR 1982 P1. m/ (file corrected … Continue reading (346) Time Travel Radio 1982 P1 (fixed) →

Offrir des jours de congés aux salariés quand ils et elles voyagent de façon plus éco-responsable. Une drôle d'idée pourtant déjà concrète. C'est l'entreprise Ubiq qui a ouvert la voie en France, la première à avoir mis en place un tel système. La société est spécialisée dans les solutions de bureaux en France.  Depuis janvier 2023, elle a mis en place le concept du TTR - le Temps de trajet responsable. Désormais, les salariés peuvent bénéficier de deux jours de congés supplémentaires par an, lorsqu'ils partent en voyage de façon plus respectueuse de l'écologie. Qu'est-ce que le temps de trajet responsable ? Comment ça marche ? Est-ce un geste principalement symbolique ? Écoutez la suite de cet épisode de "Maintenant vous savez". Un podcast Bababam Originals, écrit et réalisé par Johanna Cincinatis. Première diffusion : 3 mai 2023 À écouter aussi : Les plantes communiquent-elles vraiment entre elles ? Qu'est-ce que le néo-luddisme, ce mouvement qui traverse les époques ? Pourquoi la fin du ticket de caisse en France fait-elle débat ? Retrouvez tous les épisodes de "Maintenant vous savez". Suivez Bababam sur Instagram. Learn more about your ad choices. Visit megaphone.fm/adchoices

In her debut TTR show, Dani discussed top tips for leaders, reflects on past mistakes and answers questions about how leaders can navigate tricky situations! Dani gives 5 top tips: 1. You don't have to know it all! 2. Listen. 3. Lead by example. 4. You can't / shouldn't change everything in one go. 5. Protect your people.

Ben Vinton is the founder of Iso-Alpha, a nootropic brand focused on brain health. With an MBA and a background at Amazon retail, Ben moved into the health and wellness space about four years ago as a nutrition coach. He then started his own supplement brand, leading to the creation of Iso-Alpha one year ago.   A father of six, including three stepchildren, Ben lives in Utah, where he enjoys the outdoors and staying fit. His work with experts like Dr. Eric Khurts ensures Iso-Alpha remains at the cutting edge of science. Ben is passionate about spreading education on the potential benefits of Iso-Alpha, dedicated to enhancing mental performance and overall wellness.   Iso Alpha Website: Use Code ITP for discount https://isoalpha.com/   Medical Studies on Iso Alpha:  https://isoalpha.com/pages/medical-studies   From Ben:   Lastly I dove into one of the antimicrobial studies with Matured Hops Bitter Acids and wanted to provide some additional notes as I didn't have a clear answer for you on the show:   Antimicrobial Properties of Trans-Isohumulones (Trans-Ishoumulones are a specific type of isomerized alpha acids, modified further to enhance stability and are part of the Isohumulone complex in Iso-Alpha) Research indicates that trans-isohumulones, compounds derived from hops, exhibit significant antibacterial activity. These compounds work by: Inhibiting Harmful Bacteria: Trans-isohumulones are particularly effective against bacteria like Lactobacillus brevis. Enhancing Gut Health: By reducing harmful bacteria, they help maintain a balanced gut microbiome, which is crucial for digestion and overall health. Mechanism of Action The effectiveness of trans-isohumulones is influenced by environmental factors such as pH levels and the presence of specific ions: pH Levels: Their antibacterial activity increases in lower pH environments, where they remain undissociated and most effective. Ions: The presence of monovalent cations (like potassium and sodium) enhances their activity, while divalent cations (like magnesium) can reduce it.   Work With Me: Mineral Balancing HTMA Consultation: https://www.integrativethoughts.com/category/all-products  My Instagram: @integrativematt My Website: Integrativethoughts.com   Advertisements:   Viva Rays: Use Code ITP for a Discount https://vivarays.com/   Zeolite Labs Zeocharge: Use Code ITP for 10% off https://www.zeolitelabs.com/product-page/zeocharge?ref=ITP Magnesium Breakthrough: Use Code integrativethoughts10 for 10% OFF https://bioptimizers.com/shop/products/magnesium-breakthrough Just Thrive: Use Code ITP15 for 15% off https://justthrivehealth.com/discount/ITP15 Therasage: Use Code Coffman10 for 10% off https://www.therasage.com/discount/COFFMAN10?rfsn=6763480.4aed7f&utm_source=refersion&utm_medium=affiliate&utm_campaign=6763480.4aed7f   Chapters: 00:00 Introduction and Background 05:14 ISO Alpha: An Extract from Hops 09:21 The Benefits of ISO Alpha 14:31 The Subtle and Calming Effects of ISO Alpha 20:53 Studies on ISO Alpha 28:29 Introduction to Iso-Alpha and its Benefits 37:14 Iso-Alpha and Gut Health 46:50 Stimulating Brown Fat with Iso-Alpha 53:28 Conclusion and Future Research on Iso-Alpha   Takeaways: ISO Alpha is a brain health supplement made from an extract of hops called isohumulones. The product activates the vagus nerve and modulates dopamine release, leading to improved mood, focus, and mental clarity. ISO Alpha increases TTR protein levels, which help remove amyloid betas and plaque buildup in the brain, potentially reducing the risk of Alzheimer's. The benefits of ISO Alpha may be noticed after 60-90 days of use, and it offers a subtle and calming effect. Iso-Alpha is a natural compound derived from hops that has neuroprotective effects and reduces insulin resistance. It stimulates the vagus nerve and has potential benefits for cognitive function, weight management, and gut health. While there are no specific studies on its effects on conditions like autism or ADHD, Iso-Alpha may have positive effects in these areas. More research is needed to fully understand the potential of Iso-Alpha, but it shows promise as a natural and effective supplement.   Keywords: brain health, ISO Alpha, hops extract, isohumulones, neuroprotective, cognitive benefits, vagus nerve, dopamine release, mood, focus, mental clarity, TTR protein, amyloid betas, plaque buildup, Alzheimer's, iso-alpha, hops, neuroprotective, insulin resistance, vagus nerve, cognitive function, weight management, gut health, autism, ADHD  

Disciples! Here we go! Finally kicking off TTR 1981 with episode 333 – half the beast! There’s some great obvious bands as well as some ‘lesser-knowns’ and here’s where we start. Enough talking – let’s get rockin’! m/ (Time) Artist – Song [Album]BLOCK ONE: 0:01:00 The Tubes – Talk To Ya Later [The Completion Backward … Continue reading (333) Time Travel Radio 1981 Pt.1 →

Join us for a special live episode presented by Salomon at Vo2 Sports Co. in Collingwood, Ontario. This panel discussion, "How to Bring More Women to Trail Running," features insights from four inspiring women: Erin Doucette, Sabrine Chanda, Christina Blackley, and moderator Molly Hurford. Discover strategies and stories to inspire more women to hit the trails, and delve into the complex factors that limit access to running for different people. Don't miss this empowering conversation!   This Episode is brought to you by Consummate Athlete Event and Goal Based Training Plans, available in the Training Peaks Store. This ready to go plans are available to start whenever you are and provide a valuable and proven workouts to guide you to your goal or event. Use Code ‘CAPOD' to get 25% of any of the plans . bit.ly/PGPLANS Download  Find links to your favorite Podcast App (remember to rate and review!) https://pod.link/1100471297   Watch The Consummate Athlete Podcast on Youtube HERE Show Notes Erin Doucette is a workplace disability and injured worker advocate, mother, run lead for TTR and founder of The Trail Collective Sabrine Chanda, athlete, Arc'teryx staff, advocate for inclusion and disability awareness Christina Blackley, an athletic individual, played sports from soccer to flag football, Illustrator, and run lead for Barrie Run Ninjas Vo2 Sports Co. Solomon    Consummate Athlete Event and Goal Based Training Plans, available in the Training Peaks Store. Use Code ‘CAPOD' to get 25% of any of the plans . bit.ly/PGPLANS   SUPPORT THE SHOW Use this link to support the show (for free!) while you shop: https://amzn.to/3Aej4jl This episode is brought to you by 3 Month 100% Made for You Training Plans by Consummate Athlete – These popular plans are made from scratch for you to fit your goals, your schedule, your gear, and your goals. https://consummateathlete.com/training-plans/   Connect with Molly & Peter Subscribe to our Newsletter Book a Consultation – https://calendly.com/smartathlete Books By Molly Hurford https://amzn.to/3bOztkN Get The Consummate Athlete Book Follow The Consummate Athlete on Instagram and Facebook Follow Molly Hurford on Instagram Follow @PeterGlassford on Instagram Consummate Athlete Links for Coaching and other services   Past guests: Stacy Sims, Stephen Seiler, Simon Marshall, Frank Overton, Dean Golich, Joe Friel, Marco Altini Katerina Nash, Kelly Starrett, Geoff Kabush, Ellen Noble, Phil Gaimon, David Roche, Matt Fitzgerald, Dr. Marc Bubbs, Christopher McDougall, Rebecca Rusch, Kate Courtney, David Epstein Kelly Starrett, Juliet Starrett, and many more

Sean joins David Rintell, Head of Patient Advocacy at BridgeBio, and Mandy Rohrig, Director of Patient Advocacy at BridgeBio Gene Therapy to share his journey with ATTR. In this episode, Sean describes his initial symptoms, which included carpal tunnel syndrome and numbness in his foot and ankle, the misdiagnosis he experienced, and his eventual diagnosis at the Cleveland Clinic in Abu Dhabi. While the diagnosis was a relief it was also difficult to accept and took an emotional toll on him and those around him. Sean has found this to be a common experience of many diagnosed with ATTR. Since Sean's form of ATTR is hereditary, various members of his family have also been tested. Sean also highlights the positive changes in his life, including meeting his wife, Robin, discovering a talent for drawing, and becoming a public speaker about ATTR. Jonathan Fox, President and Chief Medical Officer of cardiorenal programs at BridgeBio, joins us again to give a medical introduction to ATTR. On this episode, Jonathan highlights the differences of the ATTR T80 variant. Previously, we learned that ATTR amyloidosis is caused by the dissociation of a protein called transthyretin, or TTR, that changes its shape and forms into fibrous clumps. These clumps of misshapen protein are deposited into various organs and peripheral nerves, including the heart, which can cause them to function abnormally. Jonathan explains the possible origin of the T80 variant and how the T80 variant symptoms can differ from ATTR-CM.   To learn more about living with amyloidosis visit Mackenzie's Mission, www.mm713.org

For the Anime Fans of the world, hearing the big three brings three fantastic shows to mind that have shaped modern anime. In the Hobby Board Game world, the big three include: Settlers of Catan, Carcassone, and today's classic Ticket To Ride. TTR is a drafting placement game where players are creating train routes across North America to get the most points. An iconic staple of the BG world, what do our bards think of it?? You'll have to watch to find out!You can find Ticket to Ride for yourself at:https://amzn.to/3UFvBJOJason and Robbie have the goal of introducing non-gamers to the amazing world of tabletop gaming. With over 35 years of modern board gaming experience, we strive to open newer gamers to a variety of games that may be fun and exciting for them.  Whether it's the theme, mechanics, or length of the game, we hope to demystify the negative stigma that often accompanies tabletop gaming and help players realize the tabletop gaming world is for everyone!We hope you accompany us on this journey … and join us at the table!Be sure to follow us on Instagram as well!https://www.instagram.com/bards_of_the_board/Chapters:0:00 Intro4:00 What We've Been Playing26:00 Ticket to Ride54:30 Cookie Scale1:03:30 Final Thoughts

With its potential to expand the horizons of what's possible for patients, CRISPR is the new darling of biotech. Reaching an important milestone in 2023 with the FDA approval of a sickle cell treatment using CRISPR, the technology is poised to break new barriers for treating patients in the near future. In this episode we talk with two companies working together on the next generation of CRISPR: editing cells within the body.  We discuss the progress and the challenge in making this breakthrough a reality. Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/

In this episode, we reveal a SPX weekly options strategy selling put credit spreads that expire the following day. This strategy uses bullish TTR readings from Alpha Crunching to determine whether or not to take the trade that day. Today's episode is from a video training recently sent to Alpha Crunching subscribers and posted in the free community. Here's the link to watch the 10m video presentation of this strategy:https://www.stockmarketoptionstrading.net/posts/55173187The TTR is a metric from https://www.alphacrunching.com that shows the tendency for the next day to close higher from the current day. TTR stands for Tomorrow's Triumph rate. Use code SPX50 at https://www.alphacrunching.com for 50% off your first month. Want to connect with myself? Find me on LinkedIn:Eric O'Rourke: https://www.linkedin.com/in/jericorourke/After that, join other listeners at https://StockMarketOptionsTrading.net and join the community for free right now where there are daily posts with clues to the where the market may be headed next. Also, Alpha Traders Club is where I host my SPX Live Chat each day for trading SPX weekly options. We focus on the premarket data and levels, technical analysis, and options flow for trading high probability trades for weekly income. Alpha Traders Club also posts Conservative Covered Call trades each week for generating weekly and monthly income trading options on high quality stocks and ETFs. Here's the link: https://www.stockmarketoptionstrading.net/spaces/12282222Disclaimer: This podcast is for informational and educational purposes only and should not be considered financial advice.

Decision Space is the podcast about decisions in board games. Nominate Decision Space for a Golden Geek Here: https://boardgamegeek.com/geekawards/boardgame (If you have any questions or difficulty, please reach out in the discord!) Join our active and welcoming Discord community, Join the crew today! (Decision Space Patreon), or Leave us a review wherever you found this podcast! Episode 164 - Ticket To Ride with Bill Collins This week we are joined by Bill Collins. You may know him as Varianor on the Decision Space Discord. In this episode, Bill, Jake, & Brendan dive deep into the decisions in this new classic family board game. We look deep at all possible actions, the timing puzzle, the implications of no hand limit, and much more decisional goodness. Then, Bill guides us through the high points of what is out there in the extended TTR universe of products.   Pre-Planners Quantum is on our radar, Taverns of Tiefenthal is a maybe. Give us some recs! Timestamps Golden Geek - 0:00 Episode Start  - 1:30 Ratings and Game Background - 4:14 Rules Overview  - 12:52 Deep Dive Discussion - 14:45   Music and Sound Credits Thank you to Hembree for our intro and outro music from their song Reach Out. You can listen to the full song on YouTube here: https://www.youtube.com/watch?v=gQuuRPfOyMw&list=TLGGFNH7VEDPgwgyNTA4MjAyMQ&t=3s You can find more information about Hembree at https://www.hembreemusic.com/.  Thank you to Flash Floods for use of their song Palm of Your Hand as a sting from their album Halfway to Anywhere: https://open.spotify.com/album/2fE6LrqzNDKPYWyS5evh3K?si=CCjdAGmeSnOOEui6aV3_nA Rules Overview Music:  Way Home by Tokyo Music Walker https://soundcloud.com/user-356546060​ Creative Commons — Attribution 3.0 Unported — CC BY 3.0 Free Download / Stream: https://bit.ly/tokyo-music-walker-way...​ Music promoted by Audio Library https://youtu.be/pJThZlOuDtI Contact We can be reached individually on Twitter at @jakefryd and @burnsidebh. You can also follow Decision Space on Instagram @DecisionSpacePod and talk to us there! If you prefer email, then hit us up at decisionspa@gmail.com. This information is all available along with episodes at our new website decisionspacepodcast.com. Byeee!

GLP-1s and BaroStim Neo revisited, a new drug for transthyretin amyloid CM, clopidogrel vs ASA years after PCI and stent, and statins are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. GLP-1s and Obesity, BaroStim Neo Revisited FDA Expands Label for CVRx Barostim System in HF https://www.medscape.com/viewarticle/fda-expands-label-cvrx-barostim-system-hf-2023a1000wsx JAMA Cardiology Special Communication – BDP https://jamanetwork.com/journals/jamacardiology/fullarticle/2810726 II. ATTR Cardiomyopathy ATTRibute-CM NEJM paper https://www.nejm.org/doi/full/10.1056/NEJMoa2305434 Circulation Review of TTR https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.111.078915 ATTR-ACT (Tafadimis) https://www.nejm.org/doi/10.1056/NEJMoa1805689 III. Clopidogrel vs ASA Years After PCI Long-term Clopidogrel Has Advantages After Coronary Stenting https://www.medscape.com/viewarticle/long-term-clopidogrel-has-advantages-after-coronary-stenting-2024a10000c8 Stop DAPT Original Trial STOP DAPT at 5 Years https://doi.org/10.1016/j.jacc.2023.10.013 Network Meta-analysis of P2Y12-I vs ASA https://doi.org/10.1016/j.jcin.2022.08.009 IV. Statin Use Statin Use Remains Low for At-Risk Patients https://www.medscape.com/viewarticle/999043 Annals of Internal Medicine Observational Study https://doi.org/10.7326/M23-1915 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Evan Hawkins is the lead singer and frontman for the popular band, Through The Roots from San Diego, CA. Having toured the country performing with top bands like Rebelution, Iration and Expendables, and making music for most of his life, Evan is a true entrepreneur and artist that is at the forefront of his craft. The parallels with running a band and running a team are undeniable. Success comes from a particular mindset to be the best at whatever it is you do and this conversation highlights that. JOIN THE DISCORD:https://www.patreon.com/bePatron?u=34554029PTG SHOW SPONSORS:LONE WOLF PAINTBALL: https://www.lonewolfpaintball.comHORMESIS PAINTBALL: https://hormesispaintball.com/HKARMY: https://www.hkarmy.com/TRANZFUSE: https://tranzlabs.com/?ref=PLAYTHEGAM...David Roque: CPA Assistant AHSBIZ@GMAIL.COMSupport the show

In this episode, I'll talk about how when it comes to options trading, you need more than the options probabilities to have an edge and to make money over time. We'll go through an example of using a put credit spread backtest as well as some new research from Alpha Crunching for trading them. The TTR is a new metric from https://www.alphacrunching.comUse code SPX50 for 50% your first month. Want to connect with myself and other listeners of this podcast?Go to https://StockMarketOptionsTrading.net and join the community for free right now where there are daily posts with clues to the where the market may be headed next. Want to trade with us?Check out our new group Alpha Traders Club on the website. https://www.stockmarketoptionstrading.net/spaces/12282222Disclaimer: Everything in this episode and on this podcast is for informational purposes only and should not be considered financial advice. There is substantial risk trading options if not done properly.

In this episode, we'll cover a new strategy that uses the TTR from https://AlphaCrunching.com The TTR = Tomorrow's Triumph Rate which shows the historical percentage of times SPX has closed higher the next day over the past two months.This strategy is geared towards trading SPX options that expire the following day. By trading 1DTE options, 3DTE on Friday, you can avoid any PDT issues but also increase the number of high probability trades using the TTR to gain an edge in the market. More research on this strategy is coming and will be posted and updated in the Alpha Traders Club at https://www.stockmarketoptionstrading.net

The following question refers to Section 7.8 of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.The question is asked by Stony Brook University Hospital medicine resident and CardioNerds Intern Dr. Chelsea Tweneboah, answered first by Mayo Clinic Cardiology Fellow and CardioNerds Academy Chief Dr. Teodora Donisan, and then by expert faculty Dr. Michelle Kittleson.The Decipher the Guidelines: 2022 AHA / ACC / HFSA Guideline for The Management of Heart Failure series was developed by the CardioNerds and created in collaboration with the American Heart Association and the Heart Failure Society of America. It was created by 30 trainees spanning college through advanced fellowship under the leadership of CardioNerds Cofounders Dr. Amit Goyal and Dr. Dan Ambinder, with mentorship from Dr. Anu Lala, Dr. Robert Mentz, and Dr. Nancy Sweitzer. We thank Dr. Judy Bezanson and Dr. Elliott Antman for tremendous guidance.Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. Question #29 A 69-year-old man was referred to the cardiology clinic after being found to have a reduced left ventricular ejection fraction and left ventricular hypertrophy. For the last several months he has been experiencing progressively worsening fatigue and shortness of breath while getting to the 2nd floor in his house. He has a history of bilateral carpal tunnel syndrome and chronic low back pain. He takes no medications. On exam, his heart rate is 82 bpm, blood pressure is 86/60 mmHg, O2 saturation is 97% breathing ambient air, and BMI is 29 kg/m2. He has a regular rate and rhythm with normal S1 and S2, bibasilar pulmonary rales, and 1+ pitting edema in both legs. EKG shows normal sinus rhythm with a first-degree AV delay and low voltages. Transthoracic echocardiogram shows a moderately depressed LVEF of 35-39%, severe concentric hypertrophy with a left ventricular posterior wall thickness of 1.5 cm and strain imaging showing globally reduced longitudinal strain with apical sparring. There is also biatrial enlargement and a small pericardial effusion. A pharmacologic nuclear stress test did not reveal any perfusion defects. A gammopathy panel including SPEP, UPEP, serum and urine immunofixation studies, and serum free light chains are unrevealing. A 99mTc-Pyrophosphate scan was positive with grade 3 uptake. In addition to starting diuretics, what is the next most appropriate step for managing for this patient? A Start metoprolol succinate B Start sacubitril/valsartan C Perform genetic sequencing of the TTR gene D Perform endomyocardial biopsy Answer #29 Explanation The correct answer is C – perform genetic sequencing of the TTR gene.   This patient has findings which raise suspicion for cardiac amyloidosis. There are both cardiac (low voltages on EKG and echocardiogram showing marked LVH with biatrial enlargement and small pericardial effusion as well as a characteristic strain pattern) and extra-cardiac (bilateral carpal tunnel syndrome and low back pain) features to suggest amyloidosis. The diagnosis of cardiac amyloidosis requires a high index of suspicion and most commonly occurs due to a deposition of monoclonal immunoglobulin light chains (AL-CM) or transthyretin (ATTR-CM). ATTR may cause cardiac amyloidosis as either a pathogenic variant (ATTRv) or as a wild-type protein (ATTRwt).   Patients for whom there is a clinical suspicion for cardiac amyloidosis should have screening for serum and urine monoclonal light chains with serum and urine immunofixation electrophoresis and serum free light chains (Class 1, LOE B-NR). Immunofixation electrophoresis (IFE) is preferred because serum or urine plasma electrophoresis (SPEP or UPEP) are less sensitive. Together, measurement of serum IFE, urine IFE, and serum FLC is >99% sensitive for AL amyloidosis.